AstraZeneca Shares Drop 6% After Phase 3 ATTR-CM Failure, $15bn Revenue Gap
AZN•AstraZeneca PLC shares plunged over 6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM heart disease trial, eroding a potential blockbuster indication. Analyst estimates suggest this setback creates roughly a $15bn shortfall toward its $80bn 2030 revenue goal, though its late-stage pipeline and oncology unit remain strong.
1. Phase 3 ATTR-CM Trial Failure
AstraZeneca’s investigational heart disease drug Wainua (eplontersen) missed its primary endpoints in the Phase 3 ATTR-CM trial, marking a rare clinical setback for the company’s cardiovascular portfolio and halting expectations for a new high‐value indication.
2. Market Reaction and Revenue Implications
Shares of AstraZeneca fell over 6% on the clinical disappointment, while Ionis Pharmaceuticals dropped more than 20% as royalty prospects evaporated; analysts now calculate the trial miss creates a roughly $15bn shortfall against AstraZeneca’s $80bn 2030 revenue target.
3. Pipeline Strength and Strategic Focus
Despite the setback, AstraZeneca’s late-stage pipeline remains robust, led by oncology assets including Tagrisso and Imfinzi, and the company plans to advance other cardiovascular and rare disease candidates to offset the impact.
